Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
Fitchett, David, Butler, Javed, van de Borne, Philippe, Zinman, Bernard, Lachin, John M, Wanner, Christoph, Woerle, Hans J, Hantel, Stefan, George, Jyothis T, Johansen, Odd Erik, Inzucchi, Silvio E
Published in European heart journal (01.02.2018)
Published in European heart journal (01.02.2018)
Get full text
Journal Article
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Barnett, Anthony H, Prof, Mithal, Ambrish, MD, Manassie, Jenny, BMedSc, Jones, Russell, MSc, Rattunde, Henning, MD, Woerle, Hans J, Prof, Broedl, Uli C, MD
Published in The lancet. Diabetes & endocrinology (01.05.2014)
Published in The lancet. Diabetes & endocrinology (01.05.2014)
Get full text
Journal Article
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Roden, Michael, Prof, Weng, Jianping, Prof, Eilbracht, Jens, PhD, Delafont, Bruno, MSc, Kim, Gabriel, MD, Woerle, Hans J, Prof, Broedl, Uli C, MD
Published in The lancet. Diabetes & endocrinology (01.11.2013)
Published in The lancet. Diabetes & endocrinology (01.11.2013)
Get full text
Journal Article
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Ridderstråle, Martin, Prof, Andersen, Knut Robert, BSc, Zeller, Cordula, Dipl-Math, Kim, Gabriel, MD, Woerle, Hans J, Prof, Broedl, Uli C, MD
Published in The lancet. Diabetes & endocrinology (01.09.2014)
Published in The lancet. Diabetes & endocrinology (01.09.2014)
Get full text
Journal Article
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Heise, Tim, MD, Jordan, Jens, MD, Wanner, Christoph, MD, Heer, Martina, PhD, Macha, Sreeraj, PhD, Mattheus, Michaela, Dipl Biomath, Lund, Søren S., MD, Woerle, Hans J., MD, Broedl, Uli C., MD
Published in Clinical therapeutics (01.10.2016)
Published in Clinical therapeutics (01.10.2016)
Get full text
Journal Article
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke ― Reply
Kaku, Kohei, Lee, Jisoo, Kaspers, Stefan, Woerle, Hans J., George, Jyothis T.
Published in Circulation Journal (25.05.2017)
Published in Circulation Journal (25.05.2017)
Get full text
Journal Article
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
Heise, Tim, MD, Jordan, Jens, MD, Wanner, Christoph, MD, Heer, Martina, PhD, Macha, Sreeraj, PhD, Mattheus, Michaela, Dipl Biomath, Lund, Søren S., MD, Woerle, Hans J., MD, Broedl, Uli C., MD
Published in Clinical therapeutics (01.10.2016)
Published in Clinical therapeutics (01.10.2016)
Get full text
Journal Article
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers
Friedrich, Christian, MD, Metzmann, Katrin, PhD, Rose, Peter, MD, Mattheus, Michaela, Pinnetti, Sabine, MD, Woerle, Hans J., MD
Published in Clinical therapeutics (2013)
Published in Clinical therapeutics (2013)
Get full text
Journal Article
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Seman, Leo, Macha, Sreeraj, Nehmiz, Gerhard, Simons, Gudrun, Ren, Bailuo, Pinnetti, Sabine, Woerle, Hans J, Dugi, Klaus
Published in Clinical pharmacology in drug development (01.04.2013)
Published in Clinical pharmacology in drug development (01.04.2013)
Get more information
Journal Article
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
Sarashina, Akiko, Koiwai, Kazuki, Seman, Leo J., Yamamura, Norio, Taniguchi, Atsushi, Negishi, Takahiro, Sesoko, Shogo, Woerle, Hans J., Dugi, Klaus A.
Published in DRUG METABOLISM AND PHARMACOKINETICS (2013)
Published in DRUG METABOLISM AND PHARMACOKINETICS (2013)
Get full text
Journal Article
Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study
Heise, Tim, MD, Mattheus, Michaela, Woerle, Hans J., MD, Broedl, Uli C., MD, Macha, Sreeraj, PhD
Published in Clinical therapeutics (01.04.2015)
Published in Clinical therapeutics (01.04.2015)
Get full text
Journal Article
Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers
Macha, Sreeraj, PhD, Koenen, Rüdiger, MD, Sennewald, Regina, MD, Schöne, Katja, Dipl-Math, Hummel, Noemi, DrSc, Riedmaier, Stephan, PhD, Woerle, Hans J., MD, Salsali, Afshin, MD, Broedl, Uli C., MD
Published in Clinical therapeutics (01.02.2014)
Published in Clinical therapeutics (01.02.2014)
Get full text
Journal Article
Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers
Macha, Sreeraj, PhD, Sennewald, Regina, MD, Rose, Peter, MD, Schoene, Katja, Dipl-Math, Pinnetti, Sabine, MD, Woerle, Hans J., MD, Broedl, Uli C., MD
Published in Clinical therapeutics (01.03.2013)
Published in Clinical therapeutics (01.03.2013)
Get full text
Journal Article
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
Tikkanen, Ilkka, Narko, Kirsi, Zeller, Cordula, Green, Alexandra, Salsali, Afshin, Broedl, Uli C, Woerle, Hans J
Published in Diabetes care (01.03.2015)
Published in Diabetes care (01.03.2015)
Get full text
Journal Article
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Rosenstock, Julio, Kahn, Steven E, Johansen, Odd Erik, Zinman, Bernard, Espeland, Mark A, Woerle, Hans J, Pfarr, Egon, Keller, Annett, Mattheus, Michaela, Baanstra, David, Meinicke, Thomas, George, Jyothis T, von Eynatten, Maximilian, McGuire, Darren K, Marx, Nikolaus
Published in JAMA : the journal of the American Medical Association (24.09.2019)
Published in JAMA : the journal of the American Medical Association (24.09.2019)
Get full text
Journal Article
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
Rosenstock, Julio, Jelaska, Ante, Frappin, Guillaume, Salsali, Afshin, Kim, Gabriel, Woerle, Hans J, Broedl, Uli C
Published in Diabetes care (01.07.2014)
Published in Diabetes care (01.07.2014)
Get full text
Journal Article
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
HÄRING, Hans-Ulrich, MERKER, Ludwig, SEEWALDT-BECKER, Elke, WEIMER, Marc, MEINICKE, Thomas, BROEDL, Uli C, WOERLE, Hans J
Published in Diabetes care (01.06.2014)
Published in Diabetes care (01.06.2014)
Get full text
Journal Article